We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » India Revokes GSK Tykerb Patent, Furthering Pharma’s IP Woes
India Revokes GSK Tykerb Patent, Furthering Pharma’s IP Woes
August 13, 2013
In yet another loss of intellectual property (IP) rights for innovative drugmakers in India, the country’s Intellectual Property Appellate Board (IPAB) has revoked a patent covering GlaxoSmithKline’s (GSK) breast cancer drug Tykerb.